ReviewTranslational lung cancer research2025
A narrative review of pathologic response in non-small cell lung cancer: challenges, implications, and future directions.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Standardizing pCR/MPR Assessment in NSCLC After Neoadjuvant Therapy: Challenges and Perspectives.Cancers · 2026Review
- Safety and pathologic response of neoadjuvant pulsed electric field ablation and systemic therapy in early-stage resectable lung cancer: case series.Journal of thoracic disease · 2026Article
- Advances in neoadjuvant immunotherapy for non-small cell lung cancer.Frontiers in immunology · 2026Review
- Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The increasing use of neoadjuvant therapy in non-small cell lung cancer (NSCLC) has magnified the importance of pathologic response as a treatment endpoint. However, there are persistent challenges in its assessment and interpretation. This review aimed to synthesize current methods and challenges in evaluating pathologic response in patients with NSCLC, summarize available assessment techniques and biomarkers, and collate current data on pathologic response to neoadjuvant treatments and the association with survival outcomes. Methods: We selected and reviewed articles proposing guidelines or approaches to the pathologic assessment of NSCLC, articles describing challenges in assessing pathologic response in NSCLC, and studies reporting pathologic response to neoadjuvant treatment and/or the association between pathologic response and survival outcomes. Data were extracted and summarized descriptively. Key Content and Findings: In this review, we summarize methods for evaluating pathologic response in patients with resectable NSCLC and highlight current challenges, including variability in pathologic response assessment, the limited standardization of techniques and biomarkers, and the difficulty of interpreting pathologic response. We also review current clinical data on pathologic response to neoadjuvant chemotherapy, radiotherapy, immunotherapy, tyrosine kinase inhibitors (TKIs), and antiangiogenic therapies, and the association between pathologic response and survival outcomes. Finally, we review and discuss the selection of optimal treatment strategies for patients who achieve a pathologic response to neoadjuvant therapy. Conclusions: Pathologic response is a valuable indicator of early response to treatment, but its current limitations necessitate a cautious and balanced approach in treatment decision-making for patients with early-stage resectable NSCLC, with consideration also given to other factors such as long-term survival and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.